April 26 (Reuters) - Johnson & Johnson JNJ.N:
JOHNSON & JOHNSON'S TAR-200 MONOTHERAPY DEMONSTRATES HIGHEST COMPLETE RESPONSE RATE WITH SUSTAINED CLINICAL BENEFITS IN PATIENTS WITH CERTAIN TYPES OF BLADDER CANCER
JOHNSON & JOHNSON - PHASE 2B STUDY: 82% ACHIEVE COMPLETE RESPONSE, 52.9% CANCER-FREE AT ONE YEAR
JOHNSON & JOHNSON - TAR-200 POTENTIAL TO TRANSFORM OUTCOMES FOR BCG-UNRESPONSIVE BLADDER CANCER
JOHNSON & JOHNSON - INITIATES FDA APPLICATION FOR TAR-200 UNDER RTOR PROGRAM
Source text: ID:nPn6mRPrna
Further company coverage: JNJ.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.